- Home
- THTX vs HLVX Comparison
THTX vs HLVX Comparison
Compare THTX & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THTX
- HLVX
- Stock Information
- Founded
- THTX 1993
- HLVX 2020
- Country
- THTX Canada
- HLVX United States
- Employees
- THTX N/A
- HLVX N/A
- Industry
- THTX Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- THTX Health Care
- HLVX Health Care
- Exchange
- THTX Nasdaq
- HLVX Nasdaq
- Market Cap
- THTX 93.3M
- HLVX 93.1M
- IPO Year
- THTX N/A
- HLVX 2022
- Fundamental
- Price
- THTX $1.72
- HLVX $1.90
- Analyst Decision
- THTX Hold
- HLVX Hold
- Analyst Count
- THTX 1
- HLVX 5
- Target Price
- THTX N/A
- HLVX $2.33
- AVG Volume (30 Days)
- THTX 178.5K
- HLVX 324.9K
- Earning Date
- THTX 02-19-2025
- HLVX 11-07-2024
- Dividend Yield
- THTX N/A
- HLVX N/A
- EPS Growth
- THTX N/A
- HLVX N/A
- EPS
- THTX N/A
- HLVX N/A
- Revenue
- THTX $84,316,000.00
- HLVX N/A
- Revenue This Year
- THTX $5.78
- HLVX N/A
- Revenue Next Year
- THTX $2.47
- HLVX N/A
- P/E Ratio
- THTX N/A
- HLVX N/A
- Revenue Growth
- THTX 5.75
- HLVX N/A
- 52 Week Low
- THTX $1.08
- HLVX $1.55
- 52 Week High
- THTX $2.18
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- THTX 50.28
- HLVX 42.75
- Support Level
- THTX $1.69
- HLVX $1.87
- Resistance Level
- THTX $1.83
- HLVX $2.15
- Average True Range (ATR)
- THTX 0.13
- HLVX 0.09
- MACD
- THTX -0.04
- HLVX -0.02
- Stochastic Oscillator
- THTX 19.30
- HLVX 21.87
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.